Zoledronate increases bone mineral density in non-ambulant children with cerebral palsy: A randomized, controlled trial.
Jakob Bie Granild-JensenBjarne Møller-MadsenGija RackauskaiteStense FarholtCharlotte SøndergaardTine Høg SørensenEsben Thyssen VestergaardBente Lomholt LangdahlPublished in: The Journal of clinical endocrinology and metabolism (2023)
Zoledronate for twelve months increased BMD Z-scores significantly without affecting growth, but first-dose side-effects were common and considerable. Studies into lower first doses and long-term outcomes are needed.